Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 7.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.1

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 45 mg - injection, modified release - excipient ingredients: polyglactin; n-methyl-2-pyrrolidone - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.,central precocious puberty (cpp),eligard 45mg 6 month is indicated for the treatment of children 2 years of age and older with central precocious puberty (cpp).

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 30 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 22.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.

United States - English - NLM (National Library of Medicine)

tolmar inc. - leuprolide acetate (unii: 37jns02e7v) (leuprolide - unii:efy6w0m8tg) - leuprolide acetate 7.5 mg in 0.25 ml - eligard® is indicated for the palliative treatment of advanced prostate cancer. hypersensitivity eligard® is contraindicated in patients with hypersensitivity to gnrh, gnrh agonist analogs or any of the components of eligard® .  anaphylactic reactions to synthetic gnrh or gnrh agonist analogs have been reported in the literature. risk summary based on findings in animal studies and mechanism of action, eligard® may cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform the drug-associated risk. expected hormonal changes that occur with eligard® treatment increase the risk for pregnancy loss. in animal developmental and reproductive studies, major fetal abnormalities were observed after administration of leuprolide acetate throughout gestation in rats. advise pregnant patients and females of reproductive potential of the potential risk to the fetus (see data) . animal data in animal developmental and reproduc

United States - English - NLM (National Library of Medicine)

tolmar inc. - leuprolide acetate (unii: 37jns02e7v) (leuprolide - unii:efy6w0m8tg) - eligard®  is indicated for the treatment of advanced prostate cancer. hypersensitivity eligard is contraindicated in patients with hypersensitivity to gnrh, gnrh agonist analogs or any of the components of eligard.  anaphylactic reactions to synthetic gnrh or gnrh agonist analogs have been reported in the literature. risk summary based on findings in animal studies and mechanism of action, eligard may cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform the drug-associated risk. expected hormonal changes that occur with eligard treatment increase the risk for pregnancy loss. in animal developmental and reproductive studies, major fetal abnormalities were observed after administration of leuprolide acetate throughout gestation in rats. advise pregnant patients and females of reproductive potential of the potential risk to the fetus (see data) . animal data in animal developmental and reproductive studies, majo

Israel - English - Ministry of Health

kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 22.5 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Israel - English - Ministry of Health

kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 45 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Israel - English - Ministry of Health

kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 7.5 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

United States - English - NLM (National Library of Medicine)

tolmar inc. - leuprolide acetate (unii: 37jns02e7v) (leuprolide - unii:efy6w0m8tg) - eligard is indicated for the treatment of advanced prostate cancer. hypersensitivity eligard is contraindicated in patients with hypersensitivity to gnrh, gnrh agonist analogs or any of the components of eligard.  anaphylactic reactions to synthetic gnrh or gnrh agonist analogs have been reported in the literature. risk summary based on findings in animal studies and mechanism of action, eligard may cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform the drug-associated risk. expected hormonal changes that occur with eligard treatment increase the risk for pregnancy loss. in animal developmental and reproductive studies, major fetal abnormalities were observed after administration of leuprolide acetate throughout gestation in rats. advise pregnant patients and females of reproductive potential of the potential risk to the fetus (see data) . data animal data in animal developmental and reproductive studies, major fetal abnormalities were observed after administration of leuprolide acetate throughout gestation.  there were increased fetal mortality and decreased fetal weights in rats and rabbits.  the effects of fetal mortality are expected consequences of the alterations in hormonal levels brought about by this drug. the safety and efficacy of eligard have not been established in females. there is no information regarding the presence of eligard in human milk, the effects on the breastfed child, or the effects on milk production. because many drugs are excreted in human milk and because of the potential for serious adverse reactions in a breastfed child from eligard, a decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. infertility males based on mechanism of action, eligard may impair fertility in males of reproductive potential [see clinical pharmacology (12.1)] . the safety and effectiveness of eligard in pediatric patients have not been established. the majority of the patients (approximately 70%) studied in the clinical trials were age 70 and older.  clinical studies of eligard did not include sufficient numbers of younger adult patients to determine if patients 65 years of age and older respond differently than younger adult patients. follow the detailed instructions below to ensure correct preparation of eligard prior to administration: step 1 use aseptic technique throughout the procedure.  gloves are recommended during mixing and administration. allow the product to reach room temperature before mixing.  once mixed, the product must be administered within 30 minutes or it should be discarded. on a clean field open the tray by tearing off the foil from the corner and remove the contents. discard the desiccant pack. remove the pre-connected syringe system from the tray. open the sterile safety needle package by peeling back the paper tab. note: syringe a and syringe b should not be lined-up yet. the product should only be administered with the co-packaged, sterile safety needle. grasp the latching button on the coupling device with your finger and thumb and press until you hear a snapping sound. the two syringes will be aligned. step 3 holding the syringes in a horizontal position, transfer the liquid contents of syringe a into the leuprolide acetate powder contained in syringe b. thoroughly mix the product for 60 cycles by pushing the contents back and forth between both syringes to obtain a uniform suspension. - a cycle is one push of the syringe a plunger and one push of the syringe b plunger. - when thoroughly mixed, the suspension will appear light tan to tan (eligard 7.5 mg) or colorless to pale yellow (eligard 22.5 mg, 30 mg, and 45 mg). step 4 step 5 while ensuring the syringe a plunger is fully pushed down, hold the coupling device and unscrew syringe b. this will disconnect syringe b from the coupling device. syringe a will remain attached to the coupling device. note:  small air bubbles will remain in the formulation – this is acceptable. step 6 continue to hold syringe b upright with the open end at the top. hold back the white plunger on syringe b to prevent loss of the product and attach the safety needle and cap. gently screw clockwise with approximately a three-quarter turn until the safety needle and cap are secure. do not overtighten, as the needle hub may become damaged which could result in leakage of the product during injection. the safety shield may also be damaged if the safety needle and cap are screwed with too much force. step 7 move the safety shield away from the needle and towards the syringe. note: should the needle hub appear to be damaged, or leak, the product should not be used. the damaged safety needle and cap should not be replaced and the product should not be injected. in the event of damage to the needle hub, use a new replacement eligard carton. follow the detailed instructions below to ensure correct administration of eligard: 1. select an injection site on the abdomen, upper buttocks, or another location with adequate amounts of subcutaneous tissue that does not have excessive pigment, nodules, lesions, or hair and hasn’t recently been used. 2. cleanse the injection-site area with an alcohol swab (not enclosed). 3. using the thumb and forefinger, grab and bunch the area of skin around the injection site. 5. inject the drug using a slow, steady push and press down on the plunger until the syringe is empty. make sure all the drug has been injected before removing the needle. 6. withdraw the needle quickly at the same 90° angle used for insertion. 7. immediately following the withdrawal of the needle, activate the safety shield using a finger/thumb or flat surface and push until it completely covers the needle tip and locks into place. 8. an audible and tactile “click” verifies a locked position. 9. check to confirm the safety shield is fully engaged. discard all components safely in an appropriate biohazard container. ©2024 tolmar manufactured by: tolmar, fort collins, co 80526     04006512 rev. 3 01/2024